Search

Displaying results 6781 - 6790 of 8195 in total
  1. Drug

    Metribolone

    go.drugbank.com/drugs/DB02998
    Experimental

    It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

  2. Drug

    Upacicalcet

    go.drugbank.com/drugs/DB20023
    Investigational

    Upacicalcet has a monoisotopic molecular weight of 351.03 Da.

  3. Drug

    Atuveciclib

    go.drugbank.com/drugs/DB20084
    Investigational

    Atuveciclib has a monoisotopic molecular weight of 387.12 Da.

  4. Drug

    Lapretolimod

    go.drugbank.com/drugs/DB20120
    Investigational

    Lapretolimod has a monoisotopic molecular weight of 1745.28 Da.

  5. Drug

    Bavtavirine

    go.drugbank.com/drugs/DB21527
    Investigational

    Bavtavirine has a monoisotopic molecular weight of 416.17 Da.

  6. Drug

    Cenacitinib

    go.drugbank.com/drugs/DB21735
    Investigational

    Cenacitinib has a monoisotopic molecular weight of 431.15 Da.

  7. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and a...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  8. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

  9. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    RGN6024 remains investigational and is not an approved drug. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.

  10. Drug

    Lemzoparlimab

    go.drugbank.com/drugs/DB17572
    Investigational

    Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Partic...